Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Biopharmaceutical Reimbursement Experts (EU)

Council Members in this Study Group: 23

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

David Sykes, Principal, PRMA Consulting Ltd.David Sykes

Principal
PRMA Consulting Ltd.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Sykes is the founding Partner of PRMA Consulting, United Kingdom. He is an expert in pricing, reimbursement, and health outcomes within pharmaceutical and medical device sectors. Mr. Sykes has over 14 years of blue chip experience at J&J, Lilly, and Organon within global, European and UK roles....

1 recent news post(s)

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Exubera - approvable is no longer reimbursable

October 24, 2007

David Sykes, Principal, PRMA Consulting Ltd.

Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the...

Th

June 18, 2007

GLG Expert Contributor

FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors | www.pipelinereview.com

This is a severe blow for the company which is now forced to consider external growth, but is not expert in out-of-France acquisitions. Rimonabant was meant to become THE sanofi-aventis blockbuster for the next 5 years at least. Also, the R&D productivity at sanofi-aventis will be questioned, since...

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Consultancy, Healthcare-Focused
  • Consultancy, Pharma-Focused
  • Individual/Small Consultancy
  • Academic Medical Center/Hospital or Clinic
  • Academic Institution*
  • Facility, Academic Medical Center
  • Other Health Insurer, Non-Profit
  • Other Healthcare Information Technology Company
  • Professional or Industry Association*

Members in this Study Group often have these job titles:

  • Director
  • Chief Executive Officer
  • Owner
  • Principal
  • Research Scientist
  • Physician - Attending Physician
  • Researcher
  • Project Manager
  • General Manager
  • Consultant

Related Study Groups

Study Group Name No. Members
Generic Pharmaceuticals Economic Experts (Germany) 48
Medical Device Experts 316
Anesthesiologists (EU) 257
Medical Tourism Experts 358
Generic Drug Economic Experts 767
Tricyclic Antipsychotic Prescribers: Psychiatrists 10
Child and Adolescent Psychiatrists (EU) 27